Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is Chief of Clinical Trials, Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Centre Tom Powles is Director of Barts Cancer Centre, St Bartholomews Hospital and Professor or Genitourinary oncology, Queen Mary University of London
…
continue reading
Experts at Queen Mary University of London
…
continue reading
Magic comes to Mile End with Brent Morris, Arthur Benjamin and Colm Mulcahy.
…
continue reading
Queen Mary, University of London is one of the UK's leading research-focused higher education institutions. With around 16,900 students and 3,800 staff, we are one of the biggest University of London colleges. We teach and research across a wide range of subjects in the humanities, social sciences, law, medicine and dentistry, and science and engineering. Based in a creative and culturally diverse area of east London, we are the only London university able to offer a completely integrated re ...
…
continue reading
This is a podcast from the Centre for the History of Emotions at Queen Mary, University of London. 'The Sound of Anger' won two gold British Podcast Awards in 2020. Subscribe on Apple Podcasts via iTunes here: https://itunes.apple.com/gb/podcast/living-with-feeling/id1186251350?mt=2
…
continue reading
Experts on Camera
…
continue reading
Stage left podcast explores performers' approaches to making their work. I teach and write about contemporary theatre and performance at Queen Mary University of London.
…
continue reading
Young journalists from The Print (the student newspaper of Queen Mary University of London), discuss issues affecting students in this podcast.
…
continue reading
Internal launch of the life sciences initiative
…
continue reading
1
David Willetts MP, Inaugural John Ramsden Memorial Lecture: Liberal Conservatism
Queen Mary, University of London
What can Liberal Conservatism do for you? The Seventy-Sixth Mile End Group event was given by David Willetts MP on the nature of Liberal Conservatism. David Linsay Willetts (born 9 March 1956) is a British Conservative Party politician and the Minister of State for Universities and Science. He is the Member of Parliament (MP) representing the constituency of Havant in Hampshire. This memorial lecture is a tribute to the life and work of John Ramsden, an eminent historian, politician and memb ...
…
continue reading
1
Professor Joseph Nye, The 2nd Michael Quinlan Lecture: What is Ethical Foreign Policy Leadership?
Queen Mary, University of London
How can we decide what is appropriate in the sphere of global politics? Prof. Joseph Nye, eminent academic, author, and politician with expertise in the field of foreign policy, defense, diplomacy and terrorism talks about his experiences within foreign policy and how he has come to his conclusions using examples like the Iraq war and nuclear weapons. For more information go to www.meg.qmul.ac.uk.
…
continue reading
…
continue reading
SEBASTIAN COTOFANA, M.D., Ph.D., Ph.D. is a professor of anatomy and trauma surgeon based in the United States. He is also an honorary professor at Pirogov University, Moscow, Russia, and holds visiting professorships at the University of Belgrade, Belgarde, Serbia, and Queen Mary University, London, England. Member of the Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands, and Centre for Cutaneous Research, Blizard Institute, Queen Mary University of Lo ...
…
continue reading
What makes a prolific political figure tick? Alastair John Campbell (born 25 May 1957) is a British journalist, broadcaster, political aide and author, best known for his work as Director of Communications and Strategy for Prime Minister Tony Blair between 1997 and 2003. In this interview from 20th June at Mile End Group, Alastair explores his recent autobiography, recounting the key parts of his, and Tony Blair's, career in politics, from the Iraq war to 9/11, and even the Premier's relatio ...
…
continue reading
1
Today's Neuroscience, Tomorrow's History - Professor Geoffrey Burnstock
Professor Geoffrey Burnstock
Supported by a Wellcome Trust Public Engagement grant (2006-2008) in the History of Medicine to Professor Tilli Tansey (QMUL) and Professor Leslie Iversen (Oxford), the History of Modern Biomedicine Research Group at Queen Mary, University of London presents a series of podcasts on the history of neuroscience featuring eminent people in the field: Professor Burnstock returned to London in 1975, becoming Head of Department of Anatomy and Developmental Biology at University College London and ...
…
continue reading
Supported by a Wellcome Trust Public Engagement grant (2006-2008) in the History of Medicine to Professor Tilli Tansey (QMUL) and Professor Leslie Iversen (Oxford), the History of Modern Biomedicine Research Group at Queen Mary, University of London presents a series of podcasts on the history of neuroscience featuring eminent people in the field: Professor Roger Ordidge studied physics at the University of Nottingham, and went on to obtain his PhD in 1981 under the supervision of Professor ...
…
continue reading
Strategies for Bending Time in Music
…
continue reading
Professor Jack Cuzick discusses IBIS-I breast cancer research
…
continue reading
1
Study undergraduate medicine in Malta with a top UK medical school
Queen Mary University of London
…
continue reading
1
Today's Neuroscience, Tomorrow's History - Professor Elizabeth Warrington
Professor Elizabeth Warrington
Supported by a Wellcome Trust Public Engagement grant (2006-2008) in the History of Medicine to Professor Tilli Tansey (QMUL) and Professor Leslie Iversen (Oxford), the History of Modern Biomedicine Research Group at Queen Mary, University of London presents a series of podcasts on the history of neuroscience featuring eminent people in the field: Professor Elizabeth Warrington completed her PhD on visual processing at the Institute of Neurology, London, and was formerly head of the Departme ...
…
continue reading
In this video, we see that mice that are given toys and placed in stimulating surroundings have healthier immune systems.
…
continue reading
📡 EURO—VISION 🛰 the podcast. A series of weekly podcasts that compile conversations with activists, scholars, fisherpeople and artists, hosted by FRAUD, around the politics of extraction, migration and international agreements that are affecting communities and ecologies on a global scale and that perpetuate European colonial legacies. Speakers include: 📢 Prof. Adekeye Adebajo, Director of the Institute for Pan-African Thought and Conversation at the University of Johannesburg, South Africa. ...
…
continue reading
1
Episode 351: ESMO 2024 review part 1: prostate cancer
18:48
18:48
Play later
Play later
Lists
Like
Liked
18:48
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
…
continue reading
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
…
continue reading
1
Episode 349: ESMO 2024 - Uromigos Japan!!
30:56
30:56
Play later
Play later
Lists
Like
Liked
30:56
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
…
continue reading
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
…
continue reading
1
Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer
17:59
17:59
Play later
Play later
Lists
Like
Liked
17:59
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
…
continue reading
1
Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC
25:47
25:47
Play later
Play later
Lists
Like
Liked
25:47
Silke Gillessen joins us to discuss her Presidential session from ESMO 2024
…
continue reading
1
Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC
31:10
31:10
Play later
Play later
Lists
Like
Liked
31:10
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC
…
continue reading
1
Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC
22:32
22:32
Play later
Play later
Lists
Like
Liked
22:32
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
…
continue reading
Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.
…
continue reading
1
Episode 342: ESMO 2024 Preview with Silke Gillessen
32:24
32:24
Play later
Play later
Lists
Like
Liked
32:24
Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024
…
continue reading
1
Episode 341: Hormone Resistance in Prostate Cancer
33:05
33:05
Play later
Play later
Lists
Like
Liked
33:05
Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer
…
continue reading
1
Episode 340: Cancer Immunity Cycle Update
41:50
41:50
Play later
Play later
Lists
Like
Liked
41:50
Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.
…
continue reading
1
Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU
18:37
18:37
Play later
Play later
Lists
Like
Liked
18:37
María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.
…
continue reading
1
Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More
25:39
25:39
Play later
Play later
Lists
Like
Liked
25:39
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics
…
continue reading
1
Episode 337: Updated NCCN Guidelines in RCC
42:38
42:38
Play later
Play later
Lists
Like
Liked
42:38
Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC
…
continue reading
1
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer
35:35
35:35
Play later
Play later
Lists
Like
Liked
35:35
Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.
…
continue reading
1
Episode 335: Novel immune therapies for renal cancer
37:31
37:31
Play later
Play later
Lists
Like
Liked
37:31
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
…
continue reading
1
Episodio 334 en español: Tres Uramigas ASCO 2024
36:33
36:33
Play later
Play later
Lists
Like
Liked
36:33
Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata
…
continue reading
1
Episode 333: The Uromigos Cup - The Netherlands
26:20
26:20
Play later
Play later
Lists
Like
Liked
26:20
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
…
continue reading
1
Episode 332: The Uromigos Cup - Germany's Entry
35:55
35:55
Play later
Play later
Lists
Like
Liked
35:55
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
…
continue reading
Aditya Bagrodia describes three new drugs/studies in NMIBC.
…
continue reading
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
…
continue reading
1
Episode 329: Japan in the Uromigos Cup qualifying round
30:48
30:48
Play later
Play later
Lists
Like
Liked
30:48
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
…
continue reading
1
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies
26:32
26:32
Play later
Play later
Lists
Like
Liked
26:32
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
…
continue reading
1
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates
24:02
24:02
Play later
Play later
Lists
Like
Liked
24:02
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
…
continue reading
1
Episode 326 ASCO24: KIM-1 in Renal Cancer
18:08
18:08
Play later
Play later
Lists
Like
Liked
18:08
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
…
continue reading
1
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer
33:44
33:44
Play later
Play later
Lists
Like
Liked
33:44
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
…
continue reading
1
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC
20:43
20:43
Play later
Play later
Lists
Like
Liked
20:43
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
…
continue reading
1
Episode 323 ASCO24: TDXD in Bladder Cancer
29:47
29:47
Play later
Play later
Lists
Like
Liked
29:47
Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.
…
continue reading
1
Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)
22:16
22:16
Play later
Play later
Lists
Like
Liked
22:16
Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.
…
continue reading
1
Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?
23:25
23:25
Play later
Play later
Lists
Like
Liked
23:25
Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.
…
continue reading
1
Episode 320: Team Canada's entry for the Uromigos Cup
23:30
23:30
Play later
Play later
Lists
Like
Liked
23:30
Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.
…
continue reading
1
Episode 319: ASCO 2024: A Preview of GU Data
33:49
33:49
Play later
Play later
Lists
Like
Liked
33:49
What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.
…
continue reading
1
Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases
31:59
31:59
Play later
Play later
Lists
Like
Liked
31:59
Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.
…
continue reading
1
Episode 317: AUA 2024 Preview with the AUA Secretary
22:16
22:16
Play later
Play later
Lists
Like
Liked
22:16
David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.
…
continue reading
1
Episode 316: APCCC 2024 Summary with Silke Gillessen
41:11
41:11
Play later
Play later
Lists
Like
Liked
41:11
Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.
…
continue reading
1
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer
18:17
18:17
Play later
Play later
Lists
Like
Liked
18:17
Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.
…
continue reading
1
Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer
25:15
25:15
Play later
Play later
Lists
Like
Liked
25:15
Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.
…
continue reading
1
Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease
35:40
35:40
Play later
Play later
Lists
Like
Liked
35:40
Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.
…
continue reading
1
Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer
23:56
23:56
Play later
Play later
Lists
Like
Liked
23:56
Jason Efstathiou and Piet Ost discuss the data for and against this approach.
…
continue reading
1
Episode 311: The Uromigos Paper of the Month - The POUT Trial
36:02
36:02
Play later
Play later
Lists
Like
Liked
36:02
Alison Birtle describes adjuvant chemotherapy in bladder cancer.
…
continue reading
1
Episode 310: Dosing and duration of drugs from a cost perspective
28:28
28:28
Play later
Play later
Lists
Like
Liked
28:28
Daniel Goldstein describes his work on this issue.
…
continue reading
1
Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer
27:13
27:13
Play later
Play later
Lists
Like
Liked
27:13
In this second part, Matt Galsky describes the OS signal data. We also look into the future.
…
continue reading
1
Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy
23:09
23:09
Play later
Play later
Lists
Like
Liked
23:09
Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.
…
continue reading
1
Episode 307: Bladder-Sparing Approaches Part 2
35:14
35:14
Play later
Play later
Lists
Like
Liked
35:14
Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.
…
continue reading
1
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC
29:56
29:56
Play later
Play later
Lists
Like
Liked
29:56
Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.
…
continue reading
1
Episode 305: FDA and Oncology Clinical Trials
29:35
29:35
Play later
Play later
Lists
Like
Liked
29:35
FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.
…
continue reading
1
Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC
30:43
30:43
Play later
Play later
Lists
Like
Liked
30:43
Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.
…
continue reading
Michael Lattanzi discusses treatment plans and research in the community.
…
continue reading
1
Episode 302: Part 2- Adjuvant Therapy in solid tumors
34:37
34:37
Play later
Play later
Lists
Like
Liked
34:37
Hans Hammers discusses trial design and patient selection in the adjuvant setting.
…
continue reading